Tildrakizumab, IL-23 mAb) was well tolerated in ankylosing spondylitis (AS) pts but did improve ASAS20 responses vs PBO.
Tweet Content
Tildrakizumab, IL-23 mAb) was well tolerated in ankylosing spondylitis (AS) pts but did improve ASAS20 responses vs PBO. 101 pts given TIL or PBO. ASAS20 response was 74% TIL vs 80% PBO. Study was terminated at week 24 for lack of efficacy. https://t.co/1PdyDbAILs https://t.co/44O23ZVvrc
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off